Pages that link to "Q37042128"

The following pages link to Phase I trial of rosiglitazone in FSGS: I. Report of the FONT Study Group (Q37042128):

Displaying 24 items.

• Effects of uridine diphosphate glucuronosyltransferase 2B7 and 1A7 pharmacogenomics and patient clinical parameters on steady-state mycophenolic acid pharmacokinetics in glomerulonephritis (Q28285877) (← links)
• An evaluation of overall effectiveness and treatment satisfaction with intravenous immunoglobulin among patients with immune thrombocytopenia (Q33431970) (← links)
• Follow-up of phase I trial of adalimumab and rosiglitazone in FSGS: III. Report of the FONT study group (Q33527568) (← links)
• Phase 1 trial of adalimumab in Focal Segmental Glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) study group (Q33584368) (← links)
• Novel therapies for resistant focal segmental glomerulosclerosis (FONT) phase II clinical trial: study design (Q33817568) (← links)
• Pioglitazone Attenuates Cystic Burden in the PCK Rodent Model of Polycystic Kidney Disease (Q34260759) (← links)
• Circulating Permeability Factors in Idiopathic Nephrotic Syndrome and Focal Segmental Glomerulosclerosis (Q34660324) (← links)
• Comparison of Direct Action of Thiazolidinediones and Glucocorticoids on Renal Podocytes: Protection from Injury and Molecular Effects (Q35188070) (← links)
• Protective effects of PPAR agonist in acute nephrotic syndrome (Q35747241) (← links)
• Limitations and Future Treatment Options in Type 2 Diabetes With Renal Impairment (Q36783886) (← links)
• In vivo alterations in drug metabolism and transport pathways in patients with chronic kidney diseases. (Q37622756) (← links)
• PPARγ and chronic kidney disease (Q37777055) (← links)
• Pathogenesis and therapy of focal segmental glomerulosclerosis: an update (Q37812564) (← links)
• Impact of glomerular kidney diseases on the clearance of drugs (Q37974647) (← links)
• Mitochondrial dysfunction in the pathophysiology of renal diseases (Q38168664) (← links)
• Chronic kidney disease: targeting prostaglandin E2 receptors (Q38223323) (← links)
• Novel therapies for FSGS: preclinical and clinical studies. (Q38363997) (← links)
• Permeability factors in nephrotic syndrome and focal segmental glomerulosclerosis (Q38738516) (← links)
• Peroxisome proliferator activating receptor-γ and the podocyte. (Q38815188) (← links)
• Phase I clinical trial of oral rosiglitazone in combination with intravenous carboplatin in cancer‐bearing dogs (Q44580484) (← links)
• Oxidative Stress and Renal Fibrosis: Recent Insights for the Development of Novel Therapeutic Strategies. (Q52674866) (← links)
• A possible influence of age on absorption and elimination of adalimumab in focal segmental glomerulosclerosis (FSGS) (Q86359357) (← links)
• Clinical Pharmacokinetics in Kidney Disease: Application to Rational Design of Dosing Regimens (Q90451490) (← links)
• Assessing the Impact of Losmapimod on Proteinuria in Idiopathic Focal Segmental Glomerulosclerosis (Q98292928) (← links)